All In Biotech

Drug Trial Radar · NCT07226986

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC)

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

123

Planned (sponsor's estimate)

Start

Dec 5, 2025

Primary completion

Jul 10, 2028

Study completion Sep 13, 2029

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu) vipivotide tetraxetan (also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter referred to as AAA617) with an androgen receptor pathway inhibitor (ARPI) in participants with metastatic castration resistant prostate cancer (mCRPC) who have failed one prior ARPI and with or without prior taxane exposure, and (b) in Phase II evaluate the preliminary efficacy of AMO959 in combination with AAA617 and ARPI in participants with mCRPC who have failed one prior ARPI, but who have not yet been exposed to taxane treatment.

Conditions

  • PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

Interventions

  • AMO959Drug

    DNA Damage Response inhibitor

  • AAA617Radiation

    PSMA-targeted radiopharmaceutical

  • EnzalutamideDrug

    Androgen receptor pathway inhibitor

  • AbirateroneDrug

    Androgen receptor pathway inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: Incidence rate of Dose-limiting toxicities (DLTs)Time frame: Up to 42 days after the first AAA617 dose administration
  2. Phase Ib: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From date of start of study treatment, assessed up to approximately 45 months
  3. Phase Ib: Number of Participants with dose adjustmentsTime frame: From date of start of study treatment, assessed up to approximately 24 months
  4. Phase Ib: Dose IntensityTime frame: From date of start of study treatment, assessed up to approximately 24 months
  5. Phase Ib: Duration of exposure to each study drugTime frame: From date of start of study treatment, assessed up to approximately 24 months
  6. Phase II: Biochemical Response (PSA50)Time frame: From date of start of study treatment, assessed up to approximately 24 months

Locations

25 sites in 7 countries. Site status is shown where the registry gives one.

  • VA Greater LA Healthcare System

    Los Angeles, California · Recruiting

  • Duke Univ Medical Center

    Durham, North Carolina · Recruiting

  • Rio Grande Urology

    El Paso, Texas · Recruiting

  • Utah Intermountain Medical Center

    Murray, Utah · Recruiting

  • Novartis Investigative Site

    Malvern, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    Melbourne, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    Melbourne, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    Murdoch, Western Australia, Australia · Recruiting

  • Novartis Investigative Site

    Bordeaux, France · Recruiting

  • Novartis Investigative Site

    Clermont-Ferrand, France · Recruiting

  • Novartis Investigative Site

    Nantes, France · Recruiting

  • Novartis Investigative Site

    Villejuif, France · Recruiting

  • Novartis Investigative Site

    Essen, Germany · Recruiting

  • Novartis Investigative Site

    München, Germany · Recruiting

  • Novartis Investigative Site

    Stuttgart, Germany · Recruiting

  • Novartis Investigative Site

    Dresden, Saxony, Germany · Recruiting

  • Novartis Investigative Site

    Naples, Italy · Recruiting

  • Novartis Investigative Site

    Cona, FE, Italy · Recruiting

  • Novartis Investigative Site

    Milan, MI, Italy · Recruiting

  • Novartis Investigative Site

    Fukuoka, Japan · Recruiting

  • Novartis Investigative Site

    Sapporo, Hokkaido, Japan · Recruiting

  • Novartis Investigative Site

    Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Granada, Andalusia, Spain · Recruiting

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.